Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1124 | Neuroendocrinology | ICEECE2012

Autoimmune thyroid disease and neuroendocrine gastric tumors: early detection and efficacy of somatostatin analogue treatment

Accardo G. , Renzullo A. , De Bellis A. , Bizzarro A. , Romano M. , Federico A. , Gravina A. , Faggiano A. , Marotta V. , Esposito D. , Bellastella A. , Pasquali D.

Autoimmune chronic thyroid disease (AITD) is associated with atrophic gastritis (CAG) in 29–42% of the cases. CAG and the consequent hypergastrinemia, listed as precancerous lesion, can predispose to neuroendocrine cells hyperplasia and the development of neuroendocrine gastric tumors (NET). Aim of this study was to evaluate the association of AITD with risk of gastric NET and the efficacy of somatostatin analogues treatment.Patients: From 2009 to 2...

ea0011p497 | Endocrine tumours and neoplasia | ECE2006

Differential expression of neurogenins by human pituitary adenomas

Fratticci A , Padronetti R , Giangaspero F , Ventura L , Piccirilli M , Esposito V , Gulino A , Alesse E , Jaffrain-Rea ML

The beta-HLH transcription factors NeuroD1 and ASH1 are frequently expressed by pituitary adenomas, both being present in all corticotroph, most clinically non-secreting (CNS) and a subset of GH and/or PRL-secreting adenomas. We wished to investigate the expression of the related beta-HLH factors neurogenins (Ngn) 1, 2 and 3 in the pituitary (n=4) and in a series of pituitary adenomas (n=45). RT-PCR was performed at different amplification cycles (up to 45) in al...

ea0029p1343 | Pituitary Basic | ICEECE2012

Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?

Jaffrain-Rea M. , Angelini M. , Occhi G. , Turchi A. , Castermans E. , Ceccato F. , Arcella A. , Esposito V. , Giangaspero F. , Pennelli G. , Daly A. , Alesse E. , Scaroni C. , Beckers A.

The aryl hydrocarbon receptor interacting protein (AIP) gene is abundantly expressed in normal somatotrophs. Somatotropinomas in patients with germline AIP mutations (AIPmut) are typically more aggressive than non-AIPmut adenomas and associated with higher GH/IGF1 secretion. AIP downregulation may also occur in sporadic somatotropinomas, especially in invasive tumours. We wished to evaluate the impact of somatostatin analogues (SSA) pre-treatment on AIP expression in sporadic ...